Dr. Vinay Prasad, the FDA’s outspoken chief medical officer, has abruptly resigned amid growing controversy over Sarepta Therapeutics’ gene therapy program. His departure follows three patient deaths linked to Elevidys and escalating scrutiny of the agency’s accelerated approval process.
Known for his rigorous stance on drug safety, Prasad had repeatedly clashed with FDA leadership over standards for gene therapy approvals. The sudden suspension of Sarepta’s clinical trials marks a dramatic reversal from earlier FDA decisions that Prasad had publicly questioned. His exit leaves critical unanswered questions about the future of groundbreaking genetic treatments.
- Dr. Vinay Prasad has abruptly resigned from the FDA amid controversy over Sarepta Therapeutics’ gene therapy Elevidys, following three patient deaths linked to the treatment.
- The FDA reversed its decision on Elevidys, allowing shipments for ambulatory Duchenne patients, while maintaining a voluntary hold for non-ambulatory cases.
- Prasad, known for his criticism of accelerated approvals, clashed with FDA leadership over drug regulation standards, particularly regarding gene therapies.
- Industry speculation suggests Prasad may return to academia or launch a platform challenging pharmaceutical oversight post-FDA departure.
Dr. Vinay Prasad’s FDA Departure: Inside the Sarepta Gene Therapy Controversy and His Next Career Move
The Unexpected Resignation: Why Did Dr. Vinay Prasad Leave the FDA?
Dr. Vinay Prasad’s sudden resignation as the FDA’s Chief Medical and Scientific Officer on July 29, 2025, sent shockwaves through the regulatory and biotech communities. His departure coincided with escalating controversy surrounding Sarepta Therapeutics’ gene therapy Elevidys, which was suspended days earlier following three patient deaths. Industry insiders suggest Prasad’s exit represents a fundamental clash between his evidence-based approach and the FDA’s accelerated approval mechanisms.
Multiple sources confirm Prasad had been advocating for stricter safety standards in gene therapy reviews since his May 2025 appointment. The timing strongly suggests his resignation stems from internal discord over the agency’s handling of Sarepta’s case. FDA insiders report heated debates between Prasad’s team and colleagues advocating for faster access to experimental therapies.
Sarepta’s Gene Therapy Crisis: What Went Wrong with Elevidys?
The Elevidys gene therapy catastrophe unfolded rapidly in July 2025 when three Duchenne muscular dystrophy patients died from acute liver failure following treatment. All cases involved Sarepta’s AAVrh74 vector – the delivery system central to their $3.2 million therapy. The FDA’s subsequent clinical hold exposed critical flaws in the accelerated approval pathway:
- Insufficient safety data from earlier trials failed to predict these fatal outcomes
- Questionable selection of dystrophin expression as a surrogate endpoint
- Failure to stratify risks for non-ambulatory patients
The Battle Over Accelerated Approvals: Prasad vs. FDA Leadership
Dr. Prasad’s tenure at the FDA was marked by continuous conflict regarding accelerated approvals – particularly for rare disease treatments. His internal memos obtained by investigative journalists reveal:
| Date | Controversial Stance |
|---|---|
| June 3 | Criticized Elevidys approval as “premature” without functional benefit proof |
| June 18 | Opposed expanded access for non-ambulatory Duchenne patients |
| July 10 | Called for suspension after first death report |
The FDA’s eventual reversal on July 18 mirrored Prasad’s recommendations, but insider accounts suggest this victory came too late to repair institutional fractures.
Career Crossroads: Where Will the “FDA Dissident” Land Next?
Industry analysts speculate about Prasad’s next career chapter based on his unique expertise and combative reputation:
- Academic research: Returning to UC San Francisco to study regulatory science
- Policy think tank: Joining Brookings or RAND to shape drug approval reforms
- Media venture: Launching a Substack or podcast critiquing pharma influence
- Pharmaceutical consulting: Advising companies on rigorous trial designs
The Ripple Effects: How This Will Transform Gene Therapy Development
The Sarepta-Prasad debacle will have lasting consequences across the biotech sector:
For Regulatory Policy
FDA will likely implement sweeping changes including:
- Longer mandatory safety monitoring periods
- Tighter restrictions on surrogate endpoints
- Stricter AAV vector safety testing
For Pharmaceutical Companies
The fallout is already evident through:
- 42% drop in gene therapy stock valuations since July
- Revised clinical trial protocols across 18 major programs
- Increased liability insurance costs for gene therapy developers
The Political Dimension: How Washington Shaped This Crisis
Prasad’s appointment and subsequent resignation reflect deeper political currents affecting the FDA:
| Factor | Impact |
|---|---|
| Kennedy administration vaccine policies | Created opening for skeptical voices |
| Congressional pressure for faster approvals | Heightened conflicts with safety advocates |
| 2024 election pharmaceutical donations | Raised questions about industry influence |
With presidential elections approaching, Prasad’s departure may signal broader shifts in FDA leadership and priorities.
Lessons for the Future: Reforming Drug Approval Systems
This controversy highlights systemic issues requiring fundamental reforms:
- Transparency: Require public disclosure of internal FDA scientific debates
- Accountability: Establish clear consequences for overlooked safety signals
- Balance: Create independent counterweights to industry pressure
Comments